血清细胞骨架蛋白4检测对肝细胞癌的诊断价值

Diagnostic value of serum cytoskeleton-associated protein 4 in hepatocellular carcinoma

摘要:

目的 探讨检测血清细胞骨架蛋白4（CKAP4）水平对识别肝细胞癌（HCC）患者的临床价值。方法 选取2013年1月—2017年12月苏州大学附属第一医院HCC患者88例为HCC组，同期选取肝硬化患者91例、慢性乙型肝炎患者87例、门诊体检部健康体检者81例作为3个对照组。血清CKAP4水平检测采用酶联免疫吸附试验（ELISA）。受试者操作特征（ROC）曲线用于评价蛋白对HCC的识别能力。结果 HCC患者的血清CKAP4水平高于肝硬化患者、慢性乙肝患者及健康体检者（P?<0.05）。CKAP4的Cut-off值为261.1 pg/ml， 判断HCC的ROC下面积（AUC）为0.843（95% CI：0.799，0.888），敏感性为0.761，特异性为0.737。CKAP4与甲胎蛋白（AFP）比较，差异无统计学意义（P?>0.05）。CKAP4判断早期HCC的AUC为0.865（95% CI：0.814，0.915），敏感性为0.784，特异性为0.737，结果优于AFP（P?<0.05）。结论 CKAP4可成为HCC诊断的血清肿瘤标志物。

Abstract:

Objective To investigate diagnostic value of circulating cytoskeleton-associated protein 4 (CKAP4) in hepatocellular carcinoma (HCC). Methods A total of 88 patients with HCC, 87 patients with chronic hepatitis B infection, 91 patients with cirrhosis, and 81 healthy controls were recruited from the First Affiliated Hospital of Soochow University during Jan. 2013 and Dec. 2017. Circulating levels of CKAP4 were evaluated with ELISA. Receiver operating characteristics (ROC) was used to evaluate diagnostic accuracy. Results Serum levels of CKAP4 increased significantly in HCC group compared with three control groups (P??0.05) to identify HCC between CKAP4 [AUC?=?0.843, (95% CI: 0.799, 0.888), sensitivity 0.761, specificity 0.737] and α-fetoprotein. CKAP4 presented better performance [AUC?=?0.865, (95% CI: 0.814, 0.915)] to early diagnosis of HCC compared with α-fetoprotein (P?